TY - JOUR
T1 - HIV-1 infected humanized DRAGA mice develop HIV-specific antibodies despite lack of canonical germinal centers in secondary lymphoid tissues
AU - Ollerton, Matthew T.
AU - Folkvord, Joy M.
AU - Peachman, Kristina K.
AU - Shashikumar, Soumya
AU - Morrison, Elaine B.
AU - Jagodzinski, Linda L.
AU - Peel, Sheila A.
AU - Khreiss, Mohammad
AU - D’Aquila, Richard T.
AU - Casares, Sofia
AU - Rao, Mangala
AU - Connick, Elizabeth
N1 - Funding Information:
Collection of normal human spleen specimens and utilization of the University of Arizona Cancer Center Flow Cytometry Shared Resource as reported in this publication were supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA023074. Support for MO was provided by the Moya-Teller Fund. This work was partially supported as a subaward on P01AI131346-04 grant awarded to RD at Northwestern University, Chicago.This work is supported in part by the US Army Medical Research and Development Command under Contract No. W81-XWH-18-C-0337 (formerly W81-XWH-16-C-0225) and by the US Military HIV Research Program, Walter Reed Army Institute of Research under a cooperative agreement (W81XWH-18-2-0040, formerly W81XWH-11-2-0174) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and the US Department of Defense (DoD). The views, opinions and/or findings are those of the authors and should not be construed to represent the positions, policy or decision of the U.S. Army, U.S. Navy, or the Department of Defense.
Publisher Copyright:
Copyright © 2022 Ollerton, Folkvord, Peachman, Shashikumar, Morrison, Jagodzinski, Peel, Khreiss, D’Aquila, Casares, Rao and Connick.
PY - 2022/11/25
Y1 - 2022/11/25
N2 - A major barrier in the use of humanized mice as models of HIV-1 (HIV) infection is the inadequate generation of virus-specific antibody responses. Humanized DRAGA (hDRAGA) mice generate antigen-specific class switched antibodies to several pathogens, but whether they do so in HIV infection and the extent to which their secondary lymphoid tissues (sLT) support germinal center responses is unknown. hDRAGA mice were evaluated for their ability to support HIV replication, generate virus-specific antibody responses, develop splenocyte subsets, and organize sLT architecture. hDRAGA mice supported persistent HIV replication and developed modest levels of gp41-specific human IgM and IgG. Spleens from uninfected and HIV infected hDRAGA mice contained differentiated B and CD4+ T cell subsets including germinal center (GC) B cells and T follicular helper cells (TFH); relative expansions of TFH and CD8+ T cells, but not GC B cells, occurred in HIV-infected hDRAGA mice compared to uninfected animals. Immunofluorescent staining of spleen and mesenteric lymph node sections demonstrated atypical morphology. Most CD4+ and CD8+ T cells resided within CD20hi areas. CD20hi areas lacked canonical germinal centers, as defined by staining for IgD-Ki67+cells. No human follicular dendritic cells (FDC) were detected. Mouse FDC were distributed broadly throughout both CD20hi and CD20lo regions of sLT. HIV RNA particles were detected by in situ hybridization within CD20+ areas and some co-localized with mouse FDC. Viral RNA+ cells were more concentrated within CD20hi compared to CD20lo areas of sLT, but differences were diminished in spleen and eliminated in mesenteric lymph nodes when adjusted for CD4+ cell frequency. Thus, hDRAGA mice recapitulated multiple aspects of HIV pathogenesis including HIV replication, relative expansions in TFH and CD8+ T cells, and modest HIV-specific antibody production. Nevertheless, classical germinal center morphology in sLT was not observed, which may account for the inefficient expansion of GC B cells and generation of low titer human antibody responses to HIV-1 in this model.
AB - A major barrier in the use of humanized mice as models of HIV-1 (HIV) infection is the inadequate generation of virus-specific antibody responses. Humanized DRAGA (hDRAGA) mice generate antigen-specific class switched antibodies to several pathogens, but whether they do so in HIV infection and the extent to which their secondary lymphoid tissues (sLT) support germinal center responses is unknown. hDRAGA mice were evaluated for their ability to support HIV replication, generate virus-specific antibody responses, develop splenocyte subsets, and organize sLT architecture. hDRAGA mice supported persistent HIV replication and developed modest levels of gp41-specific human IgM and IgG. Spleens from uninfected and HIV infected hDRAGA mice contained differentiated B and CD4+ T cell subsets including germinal center (GC) B cells and T follicular helper cells (TFH); relative expansions of TFH and CD8+ T cells, but not GC B cells, occurred in HIV-infected hDRAGA mice compared to uninfected animals. Immunofluorescent staining of spleen and mesenteric lymph node sections demonstrated atypical morphology. Most CD4+ and CD8+ T cells resided within CD20hi areas. CD20hi areas lacked canonical germinal centers, as defined by staining for IgD-Ki67+cells. No human follicular dendritic cells (FDC) were detected. Mouse FDC were distributed broadly throughout both CD20hi and CD20lo regions of sLT. HIV RNA particles were detected by in situ hybridization within CD20+ areas and some co-localized with mouse FDC. Viral RNA+ cells were more concentrated within CD20hi compared to CD20lo areas of sLT, but differences were diminished in spleen and eliminated in mesenteric lymph nodes when adjusted for CD4+ cell frequency. Thus, hDRAGA mice recapitulated multiple aspects of HIV pathogenesis including HIV replication, relative expansions in TFH and CD8+ T cells, and modest HIV-specific antibody production. Nevertheless, classical germinal center morphology in sLT was not observed, which may account for the inefficient expansion of GC B cells and generation of low titer human antibody responses to HIV-1 in this model.
KW - HIV - human immunodeficiency virus
KW - follicle
KW - germinal center (GC)
KW - humanized DRAGA mice
KW - secondary lymphoid tissue
UR - http://www.scopus.com/inward/record.url?scp=85143805149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143805149&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.1047277
DO - 10.3389/fimmu.2022.1047277
M3 - Article
C2 - 36505432
AN - SCOPUS:85143805149
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1047277
ER -